{"filings":[{"id":102089,"accession_number":"0001493152-26-011649","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Genelux enters $100M at-the-market equity offering agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.","TD Cowen receives up to 3.0% commission on gross proceeds from sales.","Proceeds for general corporate purposes, including R&D, clinical trials, and capex.","Company has no obligation to sell shares; may suspend at any time.","Shares offered via at-the-market program on Nasdaq or negotiated transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102088,"accession_number":"0001493152-26-004755","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux furnishes updated corporate presentation; no specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated February 2026 includes business and strategic updates.","No quantitative data, financial results, or material events specified in the filing or available exhibit.","Document furnished under Regulation FD and posted on investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102087,"accession_number":"0001493152-26-000989","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genelux prices $20M public offering of 6.7M shares at $3.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 6,666,667 shares at $3.00 each.","Gross proceeds of approx. $20M before underwriting discounts and expenses.","Underwriter granted 30-day option to buy up to 1,000,000 additional shares.","Proceeds for general corporate purposes including R&D, clinical trials, and working capital.","Offering expected to close January 9, 2026; sole book-runner Lucid Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102086,"accession_number":"0001493152-26-000270","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.","NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.","Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).","Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102085,"accession_number":"0001493152-26-000115","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genelux appoints Jason Litten as CMO after Paul Scigalla resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.","Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.","Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.","Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134857,"accession_number":"0001641172-25-026390","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.","Repricing covers approximately 2,715,583 shares under 2009/2019/2022 equity plans; exec holdings included.","CEO Thomas Zindrick holds 1,355,940 repriced options; other officers listed with 8,333–272,652 shares.","No changes for non-employee directors or 2023 inducement plan options; original vesting and expiry unchanged.","2025 annual meeting: Zindrick and Tyree re-elected as Class III directors; Weinberg & Company ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170657,"accession_number":"0001641172-25-000642","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.","Underwriter receives warrant to purchase 120,000 shares at $4.20 per share, exercisable after 180 days.","Proceeds for working capital and continued clinical development of Olvi-Vec.","Titan Partners Group acting as sole bookrunner; offering under effective shelf registration S-3.","Shares sold in registered direct offering; underwriting discounts and expenses not yet disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170656,"accession_number":"0001641172-25-000528","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).","Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.","FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.","Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170655,"accession_number":"0001493152-25-004554","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.","Matt Pulisic appointed CFO effective Jan 30, 2025; previously VP Finance at Arrowhead Pharmaceuticals.","Pulisic receives base salary of $410,000/year, target bonus of 40% of base, and option to purchase 275,000 shares at $3.95/share.","Option vests over 4 years (25% after one year, then monthly); full acceleration upon change in control.","Pulisic eligible for severance: 6 months base salary without cause, 12 months base salary if termination within change in control period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187635,"accession_number":"0001493152-24-044258","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux furnishes corporate presentation on November 8, 2024; no specific financial or operational updates available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Genelux made available a corporate presentation for use in investor and analyst meetings.","No financial results, guidance, or material events were announced in the filing.","The presentation includes forward-looking statements with accompanying cautionary language."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187634,"accession_number":"0001493152-24-039417","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux VP of Quality Caroline Jewett resigns effective Oct 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Caroline Jewett resigned as VP, Head of Quality, effective October 18, 2024.","No successor or interim replacement has been announced.","Departure is a voluntary resignation; no reason disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204118,"accession_number":"0001493152-24-030410","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Genelux holds 2024 annual meeting; elects two Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Mary Mirabelli as Class II director with 13,349,192 votes for, 1,386,089 withheld, and 7,740,438 broker non-votes.","Elected John Thomas, Ph.D. as Class II director with 9,417,742 votes for, 5,317,539 withheld, and 7,740,438 broker non-votes.","Ratified Weinberg & Company as independent auditor for FY 2024: 20,271,624 for, 99,110 against, 2,104,985 abstentions.","Quorum of 22,475,719 shares (65.43% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204117,"accession_number":"0001493152-24-029876","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux posts corporate presentation on August 1, 2024; no specific new data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished corporate presentation as Exhibit 99.1 under Regulation FD.","Presentation may be used by management in future meetings; no financial results or guidance provided.","Presentation content not included in this filing; summary cannot be produced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220842,"accession_number":"0001493152-24-022621","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genelux receives ~$2.35M net from partial overallotment exercise by underwriters","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to purchase 625,000 shares and warrants at $4.00 per unit.","Net proceeds after discounts and expenses were approximately $2.35 million.","Warrants have $5.25 exercise price and include a 9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220841,"accession_number":"0001493152-24-021265","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.","Each warrant exercisable at $5.25, immediately exercisable, expires 5 years from issuance.","Underwriters granted 30-day option for additional 1,031,250 shares and warrants (15% over-allotment).","Proceeds to fund working capital into Q1 2026 and Olvi-Vec development; Phase 3 OnPrime topline expected H2 2025.","Closing expected May 29, 2024; Guggenheim Securities sole bookrunner, Newbridge Securities co-manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}